EDAP TMS Reports Strong Q3 2025 Results and Secures EIB Credit Facility

EDAP TMS ( (EDAP) ) has issued an announcement.

EDAP TMS reported a significant 49% year-over-year increase in HIFU revenue for the third quarter of 2025, driven by a 167% rise in Focal One system placements and a 15% growth in U.S. procedures. The company also secured a €36 million credit facility from the European Investment Bank to support the expansion of its Focal One platform. Additionally, EDAP’s recent achievements include receiving an industry award for innovation and conducting a successful prostate cancer awareness campaign, which has enhanced its market presence and stakeholder engagement.

The most recent analyst rating on (EDAP) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on EDAP TMS stock, see the EDAP Stock Forecast page.

Spark’s Take on EDAP Stock

According to Spark, TipRanks’ AI Analyst, EDAP is a Neutral.

EDAP’s overall score is primarily impacted by its financial performance, which shows strong revenue growth but significant profitability and cash flow challenges. Technical analysis indicates bearish momentum, while valuation metrics reflect ongoing losses. The earnings call provides a positive outlook for the core HIFU business, but challenges remain in non-core areas.

To see Spark’s full report on EDAP stock, click here.

More about EDAP TMS

EDAP TMS S.A. is a global leader in robotic energy-based therapies, specializing in High-Intensity Focused Ultrasound (HIFU) technology for the treatment of early-stage prostate cancer. The company focuses on expanding its Focal One Robotic HIFU platform, which is gaining traction in the U.S. and globally due to its non-invasive treatment capabilities.

Average Trading Volume: 98,276

Technical Sentiment Signal: Sell

Current Market Cap: $75.91M

Learn more about EDAP stock on TipRanks’ Stock Analysis page.